Jpmorgan Chase & CO Dyne Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.51 Trillion
  • Q3 2025

A detailed history of Jpmorgan Chase & CO transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,365,245 shares of DYN stock, worth $58.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,365,245
Previous 2,531,313 32.94%
Holding current value
$58.7 Million
Previous $26.5 Million 60.78%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025
BUY
$8.18 - $14.22 $6.82 Million - $11.9 Million
833,932 Added 32.94%
3,365,245 $42.6 Million
Q1 2025

May 12, 2025
BUY
$10.46 - $25.46 $25.4 Million - $61.9 Million
2,432,926 Added 2472.81%
2,531,313 $26.5 Million
Q4 2024

Feb 12, 2025
SELL
$23.56 - $35.55 $79,232 - $119,554
-3,363 Reduced 3.31%
98,387 $2.32 Million
Q3 2024

Dec 26, 2024
BUY
$31.94 - $47.04 $135,297 - $199,261
4,236 Added 4.34%
101,750 $3.65 Million
Q3 2024

Nov 08, 2024
BUY
$31.94 - $47.04 $135,297 - $199,261
4,236 Added 4.34%
101,750 $3.65 Million
Q2 2024

Dec 26, 2024
SELL
$23.65 - $35.63 $100,181 - $150,928
-4,236 Reduced 4.16%
97,514 $3.44 Million
Q2 2024

Aug 12, 2024
BUY
$23.65 - $35.63 $1.02 Million - $1.54 Million
43,144 Added 79.35%
97,514 $3.44 Million
Q1 2024

Dec 26, 2024
SELL
$13.06 - $29.18 $618,782 - $1.38 Million
-47,380 Reduced 46.57%
54,370 $1.54 Million
Q1 2024

May 10, 2024
BUY
$13.06 - $29.18 $168,304 - $376,042
12,887 Added 31.07%
54,370 $1.54 Million
Q4 2023

Dec 26, 2024
SELL
$6.62 - $13.64 $398,967 - $822,041
-60,267 Reduced 59.23%
41,483 $551,000
Q4 2023

Feb 12, 2024
SELL
$6.62 - $13.64 $1.96 Million - $4.05 Million
-296,691 Reduced 87.73%
41,483 $551,000
Q3 2023

Nov 14, 2023
BUY
$8.6 - $12.18 $2.6 Million - $3.69 Million
302,562 Added 849.61%
338,174 $3.03 Million
Q2 2023

Aug 11, 2023
BUY
$8.53 - $14.28 $74,577 - $124,850
8,743 Added 32.54%
35,612 $400,000
Q1 2023

May 18, 2023
BUY
$10.88 - $15.0 $264,024 - $364,005
24,267 Added 932.63%
26,869 $309,000
Q1 2023

May 11, 2023
SELL
$10.88 - $15.0 $194,120 - $267,630
-17,842 Reduced 87.27%
2,602 $29,000
Q4 2022

Feb 13, 2023
SELL
$9.37 - $13.8 $218,620 - $321,981
-23,332 Reduced 53.3%
20,444 $237,000
Q3 2022

Nov 14, 2022
BUY
$7.2 - $15.17 $60,883 - $128,277
8,456 Added 23.94%
43,776 $557,000
Q2 2022

Aug 11, 2022
BUY
$4.36 - $10.5 $32,534 - $78,351
7,462 Added 26.79%
35,320 $242,000
Q1 2022

May 11, 2022
SELL
$6.52 - $12.27 $65,069 - $122,454
-9,980 Reduced 26.38%
27,858 $268,000
Q4 2021

Feb 10, 2022
SELL
$11.89 - $16.07 $663,997 - $897,429
-55,845 Reduced 59.61%
37,838 $450,000
Q3 2021

Nov 12, 2021
BUY
$15.6 - $21.46 $1.46 Million - $2.01 Million
93,683 New
93,683 $1.52 Million

Others Institutions Holding DYN

# of Institutions
213
Shares Held
125M
Call Options Held
36.5K
Put Options Held
74.3K
View Full List

About Dyne Therapeutics, Inc.

DYN Quotes by TradingView
  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $903M
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email